← board
FLNA
distress 3/10 · well-funded / low risk$0.93-3%today-80% from 52w high
Lead: tuberous sclerosis complex (TSC)-related epilepsy
Revenue
pre-revenue
Liquidity
$87M
Runway
2.9 yrs
Shares 1y
0%
Price & events
-60.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.2%
1D
-14.0%
1W
-21.9%
1M
-44.0%
3M
-57.8%
6M
-65.6%
1Y
-92.3%
2Y
-99.2%
5Y
-86.9%
All
Overview
- Market Cap
- $44.88M
- Volume
- 49.61K
- 52 Week Range
- $0.93 – $4.64
- Total Shares
- 48.31M
- Float Shares
- 47.32M
- Short %
- 13.71%
- % Held by Insiders
- 2.05%
- % Held by Institutions
- 28.72%
- RVOL
- 0.14x
- Beta
- -0.74
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 6
- 2026-08-13earningsEarningsEarnings releaseyahoo
- H1 2026trial initiationsecondarysimufilam · First clinical study for simufilam in TSC-related epilepsy expected to beginSEC 8-K
- 2026-02-19fda agreementDOJ closed previously-disclosed inquiry into research misconduct allegations.SEC 8-K
- 2025-12-15clinical holdsimufilam · FDA placed proposed trial for TSC-related epilepsy on full clinical hold.SEC 8-K
- 2025-03-25trial discontinuedsimufilam · Discontinued all development of simufilam for Alzheimer's diseaseSEC 8-K
- 2025-02-26partnershipsimufilam · Licensed exclusive worldwide rights from Yale to develop simufilam for TSC-related epilepsy and other indicationsSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2025-10-06LUCID CAPITAL MARKETSBuy
Competitors — tuberous sclerosis complex (TSC)-related epilepsy
- none identified
Recent news
- 2026-07-22Filana Therapeutics (FLNA) AGM 2026 Summary - Quartr
- 2026-07-22Filana Therapeutics (FLNA) Q4 2025 earnings summary - Quartr
- 2026-07-14Filana Therapeutics (FLNA) Slides 5% as Bearish Momentum Builds; Key Support at $1.04 in Focus - ATR Stop - dars.gov.et
- 2026-07-07FLNA Q3 2025 Earnings: Narrower-Than-Expected Loss Despite Stock Slide - EPS Surprise History - dars.gov.et
- 2026-07-03FLNA Should I Buy - Intellectia AI
- 2026-06-25FLNA Forecast — Price Target — Prediction for 2027 - TradingView
- 2026-06-17Filana Therapeutics (FLNA) Holds Near Support Amid Modest Decline - Factor Crowding - dars.gov.et
- 2026-06-11FLNA: All proposals passed as the company focuses on resolving the FDA clinical hold for its TSC program - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.